RESUMO
This study evaluated the potential effects of long-term land use and climate change on the quality of surface runoff and the health risks associated with it. The land use change projection 2030 was derived from the main changes in land use from 2009 to 2019, and rainfall data was obtained from the Long Ashton Research Station Weather Generator (LARS-WG) model. The Long-Term Hydrological Impact Assessment (L-THIA) model was then utilized to calculate the rate of runoff heavy metal (HM) pollutant loading from the urban catchment. It was found that areas with heavy development posed a significantly greater public health risk associated with runoff, with higher risks observed in high-development and traffic areas compared to industrial, residential, and commercial areas. Additionally, exposure to Lead (Pb), Mercury (Hg), and Arsenic (As) was found to contribute significantly to overall non-carcinogenic health risks for possible consumers of runoff. Carcinogenic risk values of As, Cadmium (Cd), and Pb were also observed to increase, particularly in high-development and traffic areas, by 2030. This investigation offers important insight into the health risks posed by metals present in surface runoff in urban catchment areas under different land use and climate change scenarios.
Assuntos
Exposição Ambiental , Metais Pesados , Poluentes Químicos da Água , Metais Pesados/análise , Humanos , Poluentes Químicos da Água/análise , Medição de Risco , Exposição Ambiental/análise , Monitoramento Ambiental , Mudança Climática , Cidades , ChuvaRESUMO
CONTEXT: Molecular testing can refine the risk of malignancy in thyroid nodules with indeterminate cytology to decrease unnecessary diagnostic surgery. OBJECTIVE: This study was performed to evaluate the outcomes of cytologically indeterminate thyroid nodules managed with Afirma genomic sequencing classifier (GSC) testing. DESIGN, SETTING, PATIENTS, AND INTERVENTION: Adult patients who underwent a biopsy at three major academic centers between July 2017 and June 2021 with Bethesda III or IV cytology were included. All patients had surgery or minimum follow-up of 1 year ultrasound surveillance. MAIN OUTCOME MEASURES: The primary outcomes were the sensitivity, specificity, PPV, and NPV of GSC in Bethesda III and IV nodules. RESULTS: The median nodule size of the 834 indeterminate nodules was 2.1 cm and the median follow-up was 23 months. GSC's sensitivity, specificity, PPV, and NPV across all institutions were 95%, 81%, 50%, and 99% for Bethesda III nodules and 94%, 82%, 65%, and 98% for Bethesda IV nodules, respectively. The overall false negative rate was 2%. The NPV of GSC in thyroid nodules with oncocytic predominance was 100% in Bethesda III nodules and 98% in Bethesda IV nodules. However, the PPV of oncocytic nodules was low (17% in Bethesda III nodules and 45% in Bethesda IV nodules). Only 22% of thyroid nodules with benign GSC results grew during surveillance. CONCLUSIONS: GSC is a key tool for managing patients with indeterminate cytology, including the higher-risk Bethesda IV category. GSC benign thyroid nodules can be observed similarly to thyroid nodules with benign cytology.
RESUMO
CONTEXT: Active surveillance for papillary thyroid cancer (PTC) meeting criteria for surgical resection is uncommon. Which patients may prove reasonable candidates for this approach is not well defined. OBJECTIVE: This work aimed to examine the feasibility and safety of active surveillance for patients with known or suspected intrathyroidal PTC up to 4â cm in diameter. METHODS: A retrospective review was conducted of all consecutive patients who underwent nonoperative active surveillance of suspicious or malignant thyroid nodules over a 20-year period from 2001 to 2021. We included patients with an initial ultrasound-fine-needle aspiration confirming either (a) Bethesda 5 or 6 cytology or (b) a "suspicious" Afirma molecular test. The primary outcomes and measures included the rate of adverse oncologic outcomes (mortality and recurrence), as well as the cumulative incidence of size/volume growth. RESULTS: Sixty-nine patients were followed with active surveillance for 1 year or longer (average 55 months), with 26 patients (38%) having nodules 2â cm or larger. No patients were found to develop new-incident occurrence of lymph node or distant metastasis. One patient, however, demonstrated concern for progression to a dedifferentiated cancer on repeat core biopsy 17 years after initial start of nonoperative selection. A total of 21% of patients had an increase in maximum diameter more than 3 mm, while volume increase of 50% or greater was noted in 25% of patients. Thirteen patients ultimately underwent delayed (rescue) surgery, and no disease recurrence was noted after such treatment. Age and initial nodule size were not predictors of nodule growth. CONCLUSION: These data expand consideration of active surveillance of PTC in select patients with intrathyroidal suspected malignancy greater than 1â cm in diameter. Rescue surgery, if required at a later time point, appears effective.